Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area's top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th. (The next session is scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here("EIR resource" at BHI). For questions/more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it..

44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1. Only 16% had received a Phase II award. The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore. However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.

Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.

New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 billion.

MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

Francis deSouza Photographer: Jeff Spicer/PA Wire via AP For years, the cost to decode a full human genome has been falling much like computer processing costs -- from hundreds of thousands of dollars per person to about $1,000 today. With a $100 genome getting closer, the CEO of the top maker of DNA sequencers thinks the world may not be ready.

The biomedical research community has made major progress in achieving a balance of men and women in human studies, however compelling questions about the underlying mechanisms that increase women’s risk or resilience for certain heart, lung, blood, and sleep (HLBS) diseases continue to challenge the scientific and medical community.

In support of its Strategic Vision, the National Heart, Lung, and Blood Institute (NHLBI) is advancing a scientific research agenda for women’s health. As part of that agenda, the Institute has issued a Request for Information “Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders.” The RFI offers the research community, health care professionals, patient advocates, and others an opportunity to provide input on topics ranging from scientific gap areas in mechanisms of HLBS diseases, to training and resource needs, among other topics.

The NHLBI greatly values your perspective as it works with the wider scientific community to uncover the mechanisms of disease that will set a stronger foundation for clinical research focused on more effective prevention and treatment strategies for HLBS diseases and disorders in women. Please submit your responses via email to This email address is being protected from spambots. You need JavaScript enabled to view it. by March 15, 2019. Don’t forget to include the Notice number (NOT-HL-18-660) in the subject line.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors.

Biopharma companies have long been looking for a way to go beyond the molecule/pill.The nascent but growing digital therapeutics industry set to grow to $10 billion by 2023 may be guiding that way forward, according to a panel discussion on the second day of the DTx (Digital Therapeutics) West conference in San Mateo, California.